US drugmakers turn to China for licensing deals
来源：Reuters发布于 2026-09-28
Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-develop...
相关标的：MRK
本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。